Galectin Therapeutics (GALT) Interest Coverage Ratio (2011 - 2026)
Galectin Therapeutics (GALT) posted quarterly Interest Coverage Ratio of 2.05 for Q1 2026, up 54.71% year-over-year from 1.33 in Q1 2025, and down 342.95% quarter-over-quarter from 0.46 in Q4 2025.
Galectin Therapeutics (GALT) Interest Coverage Ratio (2011 - 2026) Analysis & Trends
Galectin Therapeutics' Interest Coverage Ratio history runs 16 years deep, the most recent figure standing at 2.05 for Q1 2026.
- In Q1 2026, Interest Coverage Ratio rose 54.71% year-over-year to 2.05; the TTM figure through Mar 2026 stood at 1.26 (up 68.87% YoY), while the FY2025 annual figure was 0.21, up 55.3% from the prior year.
- Interest Coverage Ratio for Q1 2026 stood at 2.05, down from 0.46 in the prior quarter.
- The five-year high for Interest Coverage Ratio was 0.46 in Q4 2025, with the low at 173.84 in Q4 2023.
- The 5-year median for Interest Coverage Ratio is 9.17 (2024), against an average of 22.68.
- The sharpest annual moves came in 2023 and 2024: Interest Coverage Ratio plunged 1343.6% in 2023, then surged 98.71% in 2024.
- Galectin Therapeutics' Interest Coverage Ratio stood at 12.04 in 2022, then sank by 1343.6% to 173.84 in 2023, then soared by 98.71% to 2.24 in 2024, then jumped by 79.36% to 0.46 in 2025, then tumbled by 342.95% to 2.05 in 2026.
- Business Quant data shows GALT's Interest Coverage Ratio at 2.05 in Q1 2026, 0.46 in Q4 2025, and 2.31 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Galectin Therapeutics | 226.55 Mn | 226.55 Mn | - | -2.05 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.05 |
| Dec 31, 2025 | -0.46 |
| Sep 30, 2025 | -2.31 |
| Jun 30, 2025 | -2.53 |
| Mar 31, 2025 | -4.53 |
| Dec 31, 2024 | -2.24 |
| Sep 30, 2024 | -6.07 |
| Jun 30, 2024 | -8.90 |
| Mar 31, 2024 | -9.17 |
| Dec 31, 2023 | -173.84 |
| Sep 30, 2023 | -10.98 |
| Jun 30, 2023 | -13.85 |
| Mar 31, 2023 | -22.48 |
| Dec 31, 2022 | -12.04 |
| Sep 30, 2022 | -30.19 |
| Jun 30, 2022 | -40.09 |
| Mar 31, 2022 | -43.77 |
| Dec 31, 2021 | -128.02 |
| Sep 30, 2021 | -74.27 |
| Jun 30, 2021 | -96.39 |